SEC Charges Zymergen Inc. With Misleading IPO Investors About Company's Market Potential and Sales Prospects
September 14, 2024
September 14, 2024
WASHINGTON, Sept. 14 -- The Securities and Exchange Commission issued the following news release:
The Securities and Exchange Commission today announced settled charges against Zymergen Inc., an Emeryville, California-based biotechnology company, for misleading IPO investors about its overall market potential, revenue prospects, and customer pipeline for its only commercially available product, an electronics film named Hyaline. Zymergen raised approximately $530 million through its . . .
The Securities and Exchange Commission today announced settled charges against Zymergen Inc., an Emeryville, California-based biotechnology company, for misleading IPO investors about its overall market potential, revenue prospects, and customer pipeline for its only commercially available product, an electronics film named Hyaline. Zymergen raised approximately $530 million through its . . .